$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

$slrx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000161521922000124 Filed on August 05, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.832M	$1.836M	$1.678M
YoY Change	5.85%	15.36%	26.15%
% of Gross Profit
Research & Development	$3.790M	$2.922M	$4.439M
YoY Change	88.01%	39.37%	155.05%
% of Gross Profit
Depreciation & Amortization	$1.670K	-$1.460K	$4.797K
YoY Change	-65.21%	-115.22%	0.04%
% of Gross Profit
Operating Expenses	$14.49M	$4.758M	$6.117M
YoY Change	286.69%	29.0%	99.04%
Operating Profit	-$14.49M	-$4.758M	-$6.117M
YoY Change	286.69%	52.65%	238.98%
Interest Expense	$78.27K	$33.20K	$2.196K
YoY Change	15972.28%	12429.06%	-276.1%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$14.41M	-$4.718M	-$6.109M
YoY Change	285.58%	53.47%	230.23%
Income Tax
% Of Pretax Income
Net Earnings	-$14.41M	-$4.718M	-$6.109M
YoY Change	285.58%	53.47%	229.89%
Net Earnings / Revenue
Basic Earnings Per Share	-$6.41	-$0.09	-$0.13
Diluted Earnings Per Share	-$6.41	-$0.09	-$0.13
COMMON SHARES
Basic Shares Outstanding	56.12M shares	53.52M shares	46.26M shares
Diluted Shares Outstanding	2.248M shares	53.52M shares	46.26M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.82M	$22.65M	$24.19M
YoY Change	-47.28%	-31.54%	-33.9%
Cash & Equivalents	$16.80M	$22.65M	$24.19M
Short-Term Investments
Other Short-Term Assets	$248.7K	$215.6K	$195.4K
YoY Change	161.11%	52.34%	-5.38%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$17.97M	$23.02M	$24.86M
YoY Change	-48.94%	-39.92%	-40.32%
LONG-TERM ASSETS
Property, Plant & Equipment			$4.190K
YoY Change			-77.89%
Goodwill	$0.00	$8.866M	$8.866M
YoY Change	-100.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$146.5K	$162.4K	$170.9K
YoY Change	-27.27%	-25.08%	-26.34%
Total Long-Term Assets	$1.757M	$10.64M	$10.65M
YoY Change	-80.65%	16.94%	16.83%
TOTAL ASSETS
Total Short-Term Assets	$17.97M	$23.02M	$24.86M
Total Long-Term Assets	$1.757M	$10.64M	$10.65M
Total Assets	$19.72M	$33.65M	$35.51M
YoY Change	-55.44%	-29.01%	-30.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.717M	$1.875M	$1.693M
YoY Change	39.0%	46.94%	7.59%
Accrued Expenses	$1.394M	$895.1K	$390.2K
YoY Change	331.06%	316.95%	290.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.110M	$2.770M	$2.092M
YoY Change	92.92%	78.28%	4.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.110M	$2.770M	$2.092M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.110M	$2.770M	$2.092M
YoY Change	92.92%	78.28%	5.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.43M	-$43.02M	-$38.31M
YoY Change	104.45%	76.66%	80.0%
Common Stock	$224.00	$5.611K	$4.669K
YoY Change	-95.04%	25.33%	4.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$16.61M	$30.88M	$33.42M
YoY Change
Total Liabilities & Shareholders Equity	$19.72M	$33.65M	$35.51M
YoY Change	-55.44%	-29.01%	-30.06%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$14.41M	-$4.718M	-$6.109M
YoY Change	285.58%	53.47%	229.89%
Depreciation, Depletion And Amortization	$1.670K	-$1.460K	$4.797K
YoY Change	-65.21%	-115.22%	0.04%
Cash From Operating Activities	-$5.741M	-$3.620M	-$3.521M
YoY Change	262.9%	13.91%	29.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$1.500M
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$1.500M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-85.69K	2.073M	$0.00
YoY Change	-121.09%	-673.23%	-100.0%
NET CHANGE
Cash From Operating Activities	-5.741M	-3.620M	-$3.521M
Cash From Investing Activities	0.000	0.000	-$1.500M
Cash From Financing Activities	-85.69K	2.073M	$0.00
Net Change In Cash	-5.827M	-1.547M	-$5.021M
YoY Change	395.62%	-56.3%	-119.69%
FREE CASH FLOW
Cash From Operating Activities	-$5.741M	-$3.620M	-$3.521M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9520698	shares
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2450 Holcombe Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite X
	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
	dei	Local Phone Number LocalPhoneNumber	834-6992
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Central Index Key EntityCentralIndexKey	0001615219
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77021
	dei	City Area Code CityAreaCode	832
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#GrantMember
CY2021Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#GrantMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#GrantMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#GrantMember
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36812
	dei	Entity Registrant Name EntityRegistrantName	SALARIUS PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5087339
	dei	Security12b Title Security12bTitle	Common Stock, $ 0.0001 par value
	dei	Trading Symbol TradingSymbol	SLRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56116243	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22647005	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29214380	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	368161	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	949215	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	23015166	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	30163595	usd
CY2022Q2	us-gaap	Grants Receivable Noncurrent GrantsReceivableNoncurrent	1610490	usd
CY2021Q4	us-gaap	Grants Receivable Noncurrent GrantsReceivableNoncurrent	1610490	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	162419	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	193874	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8865909	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8865909	usd
CY2022Q2	us-gaap	Assets Assets	33653984	usd
CY2021Q4	us-gaap	Assets Assets	40833868	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1874749	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1543096	usd
CY2022Q2	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	895106	usd
CY2021Q4	flks	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	567787	usd
CY2022Q2	us-gaap	Liabilities Liabilities	2769855	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2110883	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56116243	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45241808	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56116243	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45241808	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	5611	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4524	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	73903273	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70915653	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43024755	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32197192	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30884129	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38722985	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33653984	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40833868	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	571387	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1840216	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2921572	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17807776	shares
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2096302	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7361047	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3836957	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1836395	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1591905	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3514149	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2924674	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4757967	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	3688207	usd
	us-gaap	Operating Expenses OperatingExpenses	10875196	usd
	us-gaap	Operating Expenses OperatingExpenses	6761631	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4757967	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3116820	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10875196	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4921415	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6427	usd
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-42186	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12235	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3868	usd
CY2022Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	33202	usd
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	265	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	35398	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-982	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4718338	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3074369	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-10827563	usd
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-4926265	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4718338	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3074369	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10827563	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4926265	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53522468	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53522468	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44756201	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44756201	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49908914	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49908914	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37654521	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37654521	shares
	us-gaap	Net Income Loss NetIncomeLoss	-10827563	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4926265	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3340	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9591	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	513431	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	282835	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1987900	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12235	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3868	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	938923	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-609170	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-417662	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	245959	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-577877	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	339553	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-168461	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7140445	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5897570	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1500000	usd
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1500000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	2073070	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	26850022	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1485351	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	477028	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2073070	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27858345	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6567375	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21960775	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29214380	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11118614	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22647005	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33079389	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	1468	usd
	us-gaap	Stock Issued1 StockIssued1	487900	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	flks	Stock Issuance Costs Accrued And Amortized StockIssuanceCostsAccruedAndAmortized	85694	usd
	flks	Stock Issuance Costs Accrued And Amortized StockIssuanceCostsAccruedAndAmortized	0	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	22159188	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26850021	usd
CY2021Q1	flks	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1485351	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	135379	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-1851896	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	48778043	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	147456	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3074369	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	45851130	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38722985	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	487900	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	313903	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6109225	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	33415563	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1987376	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	174528	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	25000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4718338	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30884129	usd
CY2021Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the FASB ASC requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.</span></div>
CY2022Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments and Credit Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk include cash and cash equivalents and restricted cash. Cash is deposited in demand accounts in federally insured domestic institutions to minimize risk. Insurance is provided through the Federal Deposit Insurance Corporation (“FDIC”). Although the balances in these accounts exceed the federally insured limit from time to time, the Company has not incurred losses related to these deposits.</span></div>
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1600000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1600000	usd
CY2022Q2	flks	Prepaid Clinical Trial Expense PrepaidClinicalTrialExpense	34663	usd
CY2021Q4	flks	Prepaid Clinical Trial Expense PrepaidClinicalTrialExpense	97557	usd
CY2022Q2	us-gaap	Prepaid Insurance PrepaidInsurance	117856	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	678672	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	215642	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	172986	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	368161	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	949215	usd
CY2022Q2	flks	Revenue From Grants Revenue Sharing Payments Continued Payments Percent Of Net Sales RevenueFromGrantsRevenueSharingPaymentsContinuedPaymentsPercentOfNetSales	0.01
CY2022Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	usd
CY2022Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1500000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	23000000	usd
CY2020Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.182
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
CY2022Q2	flks	Warrants And Rights Exercisable Term WarrantsAndRightsExercisableTerm	P6M
	flks	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	0	shares
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1500000	usd
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	14752165	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	142711	shares
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.17
CY2021Q3	flks	Class Of Warrant Or Right Threshold Consecutive Trading Days ClassOfWarrantOrRightThresholdConsecutiveTradingDays	10	d
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y6M21D
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y21D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1284000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	68500	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	500000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0162
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0170
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0109
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.01
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.2519
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.2642
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.3106
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3335
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1563972	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.78
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M19D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	175770	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	68500	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	45000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1587472	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.77
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M26D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	307100	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	156519	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	33750	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1597972	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.75
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1284000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.47
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2869972	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.74
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	856891	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M21D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1200000	usd
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1100000	usd

Files In Submission

Name	View Source	Status
0001615219-22-000124-index-headers.html	Edgar Link	pending
0001615219-22-000124-index.html	Edgar Link	pending
0001615219-22-000124.txt	Edgar Link	pending
0001615219-22-000124-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
flks-20220630.htm	Edgar Link	pending
flks-20220630.xsd	Edgar Link	pending
flks-20220630_cal.xml	Edgar Link	unprocessable
flks-20220630_def.xml	Edgar Link	unprocessable
flks-20220630_htm.xml	Edgar Link	completed
flks-20220630_lab.xml	Edgar Link	unprocessable
flks-20220630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slrx20220630ex-311.htm	Edgar Link	pending
slrx20220630ex-312.htm	Edgar Link	pending
slrx20220630ex-321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx

2022 Q3 Form 10-Q Financial Statement

#000161521922000124 Filed on August 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX Salarius Pharmaceuticals, Inc. Stock $slrx

2022 Q3 Form 10-Q Financial Statement

#000161521922000124 Filed on August 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLRX
Salarius Pharmaceuticals, Inc. Stock $slrx